Conagra's Earnings Fell 23% as a Held Dividend Strains a $7.3 Billion Balance Sheet

---

There is a particular relief that comes with owning a packaged-food company. The brands are old, the demand is non-negotiable — people eat in recessions — and the dividend arrives quarter after quarter like clockwork. Conagra Brands has spent decades cultivating exactly that reputation: a portfolio of household names, a position in the center of the American grocery store, and a yield generous enough that, by mid-2026, the stock was trading with a dividend yield north of nine percent. To an income investor scanning a screener, that number reads as a gift. To a forensic eye, a yield that high is rarely a gift. It is the market pricing in a question the company would prefer you not ask: can this dividend survive?

Conagra's third-quarter fiscal 2026 report, released on April 1, 2026, was framed as a turn. After several quarters of soft demand, sales had "returned to growth." Organic net sales rose 2.4%. The refrigerated and frozen business — the company's strategic heart — posted organic growth of 3.6%. Management narrowed its full-year guidance and reaffirmed its commitment to the dividend. The press release was, in the way of all earnings releases, an exercise in foregrounding the favorable. The job here is to read what was placed in the background.

The headline that points the wrong way

Start with the number that led the coverage: organic net sales up 2.4%. It is real, and it is not nothing. But the same quarter saw total net sales fall 1.9%, to $2,787.8 million. The gap is the work of divestitures — Conagra has been selling off pieces of itself — and it matters because the headline organic figure measures the business the company chose to keep, growing modestly, while the consolidated entity that actually generates the cash to service debt and pay dividends got smaller. "Return to growth" is a claim about a subset. The whole shrank.

Then look at how the 2.4% organic number was built. Of that growth, price/mix contributed 1.9 points and volume just 0.5 points. After several years in which Conagra, like every packaged-food maker, pushed through aggressive list-price increases to offset inflation, the well of pricing power is running shallow. Volume — the count of actual units leaving shelves, the truest read on whether consumers still want the product at the price — barely moved. The company is not selling meaningfully more food. It is, for the most part, charging a little more for roughly the same amount, in a quarter where even that arithmetic produced only fractional real growth. That is the signature of a business that has run its pricing lever close to the end of its travel.

Where the earnings actually went

Now to the number that the "return to growth" framing works hardest to keep out of the first paragraph. Adjusted earnings per share — the figure management itself directs investors toward — fell 23.5% year over year, to $0.39. That is not a rounding wobble. That is roughly a quarter of the company's per-share profit erased in twelve months. The headline GAAP diluted EPS of $0.42 was actually up 40% from the prior year, which sounds like the opposite story — but that GAAP figure is flattered by below-the-line items and is precisely why Conagra, like its peers, points you to the adjusted number in normal times. When the adjusted number is ugly and the GAAP number is pretty, the burden of explanation flips, and it is worth noticing which one the bullish read leans on.

The deterioration runs straight through the margin structure. Reported gross margin fell 141 basis points to 23.6%; adjusted gross margin fell 112 basis points to 23.7%. Adjusted operating margin dropped a striking 213 basis points to 10.6%. Adjusted EBITDA — the cash-proxy that a leveraged balance sheet ultimately leans on — declined 14.9% to $437 million. This is the part of the story the organic-sales headline cannot touch: even where the company managed to nudge revenue, the cost of producing that revenue rose faster. Input inflation, the perennial enemy of the food processor, did exactly what input inflation does to a commodity price-taker. Conagra raised prices; its own costs rose more.

The commodity price-taker, exposed

A consumer-staples company likes to present itself as a brand business — a custodian of consumer affection, insulated from the grubby swings of raw-material markets. The reality for a packaged-food manufacturer is closer to the opposite. Conagra buys enormous quantities of agricultural commodities, packaging, and energy, and it sells into a retail channel dominated by a handful of giant grocers and club stores with their own pricing leverage. When input costs spike, the company can attempt to pass them through — but only until consumers, or the retailers acting as their proxies, push back. The Q3 margin compression is the audited evidence of exactly that squeeze: costs the company does not control rising faster than the prices it is able to charge.

This is why the "secular brand" framing should be treated with suspicion when applied to results like these. The margin damage is not a one-off charge or a discrete event. It is the structural exposure of a business that sits between commodity markets it cannot dictate and a retail oligopsony it cannot dictate to either. In good cost environments that exposure is invisible. In bad ones it is the whole story. A 213-basis-point collapse in adjusted operating margin is not the profile of a company with a moat around its pricing. It is the profile of a price-taker.

The denominator that flatters the segments

Watch the segment table closely, because it contains a small but instructive sleight of arithmetic. Grocery & Snacks — historically the engine — reported net sales of $1,167.1 million, down 6.3% on a reported basis, even as the company reports organic growth of 1.8% in that segment. The wedge between the two is divestiture: pieces sold off, removed from the comparison base. Refrigerated & Frozen, the strategic showpiece, posted net sales of $1,133.2 million, up only 1.6% reported despite organic growth of 3.6% — again, a reported number well below the organic one. International grew 1.3% reported but organic sales there actually fell 1.2%. Foodservice was the lone clean win, up 1.8% reported and 3.6% organic.

The lesson is the same lesson the consolidated number teaches. Conagra is a company actively reshaping itself by selling assets, and that reshaping means the headline organic figures and the reported figures point in different directions across nearly every segment. When organic growth consistently exceeds reported growth, it is because the business is getting smaller in absolute terms — the denominator is being managed down. Smaller can be smarter; shedding low-return lines is a legitimate strategy. But it is not the same thing as growth, and an investor relying on the dividend needs to know that the cash-generating base is contracting even where the percentages look green.

The dividend math that the yield is screaming about

Here is the crux, and it is arithmetic, not opinion. Conagra is paying an annual dividend of $1.40 per share — $0.35 a quarter. The company's own full-year fiscal 2026 guidance now calls for adjusted EPS of approximately $1.70, at the low end of its prior $1.70-to-$1.85 range, a figure it walked down in the same April report. That implies a payout ratio in the neighborhood of eighty-two percent of adjusted earnings — and adjusted earnings are the friendlier, higher number. Against GAAP earnings the coverage is thinner still, and against the trajectory — adjusted EPS down 23.5% in the quarter — the cushion is shrinking, not building.

A payout ratio that high, on a falling earnings line, is the financial equivalent of a smoke alarm. It is exactly why the stock yields what it yields: the market is not generously rewarding income investors, it is discounting the probability that the dividend gets cut. Management, for its part, held the payout in Q3 and signaled its intent to defend it. That is a choice with consequences. Every dollar sent out the door as a dividend is a dollar not used to pay down the $7.3 billion of net debt or to reinvest in the volume problem. Defending a dividend out of a declining earnings stream is sustainable only as long as the decline is temporary. The forensic question is whether it is.

Seven billion in debt at 3.83 times

Conagra ended the quarter with net debt of $7.3 billion and a net leverage ratio of 3.83 times adjusted EBITDA. To the company's genuine credit — a point the bull case is entitled to make and which is conceded below — that net debt figure was down about 10% from the prior-year period, an $818 million reduction. Deleveraging is happening, and that is exactly the right priority for a company in this position.

But leverage is a ratio, and ratios have two sides. Net debt fell; so did EBITDA, by 14.9% in the quarter. A leverage ratio is debt divided by earnings, and when the denominator is falling, the numerator has to fall just to keep the ratio still — and has to fall faster to improve it. At 3.83 times, Conagra has meaningful but not catastrophic leverage; it is not a balance sheet in crisis. It is, however, a balance sheet with no spare capacity for a prolonged earnings decline. The company is trying to do three expensive things at once: pay down debt, defend a high dividend, and reinvest to revive volume. Falling EBITDA means it cannot fully do all three. Something gives. The market's nine-percent-plus yield is a bet on which thing gives first.

Cyclical squeeze priced — by some — as a secular turn

The most seductive version of the bull case is that the worst is behind. Input inflation will moderate; pricing will catch up to costs; the refrigerated and frozen recovery (helped this quarter by lapping prior-year supply constraints) will broaden; deleveraging will continue; and the dividend, defended through the trough, will look like a bargain entry point in hindsight. That is a coherent story, and if the cost environment cooperates it could even be the right one.

The forensic counter is that the report gives you no evidence the trough is over — it gives you evidence the trough is here. Guidance was cut, not raised. Margins compressed, they did not stabilize. Volume grew half a point, not convincingly. The company is leaning on divestitures to make the organic line look better than the consolidated line. None of that proves a permanent decline. But it means anyone buying the "secular turn" thesis is paying today for an improvement that has not yet shown up in a single line of the financials. In a stretched-consumer environment, with private-label competition pressing every center-store category and weight-management drugs quietly reshaping how Americans snack, the assumption that demand simply springs back is doing a great deal of unearned work.

What the bulls genuinely get right

It would be dishonest to leave it there, because the bull case has real substance and deserves a fair hearing. First, the deleveraging is genuine and well-directed: cutting net debt by roughly $818 million, more than 10%, in a single year is exactly what a responsibly run leveraged staples company should do, and it materially lowers the long-term risk in the equity. Second, sales did return to organic growth — 2.4% overall, with a credible 3.6% in the strategically important refrigerated and frozen business and the same in Foodservice. That is not a company in free-fall; it is a company with stabilizing demand in its core.

Third, the portfolio is real. Birds Eye, Healthy Choice, Marie Callender's, Slim Jim, Duncan Hines, Reddi-wip — these are durable brands with shelf positions that private label cannot trivially dislodge, and frozen and snacking are structurally better categories than ambient canned goods. Fourth, much of the pain is cyclical input inflation, and input costs are, by nature, mean-reverting; a calmer commodity environment would flow straight back to the margin line. Fifth, the valuation already reflects a great deal of pessimism — a high-single-to-double-digit yield and a low earnings multiple mean expectations are on the floor, which is precisely the setup from which staples names have historically delivered their best returns when sentiment stops getting worse. And finally, management is not in denial: it cut guidance honestly rather than papering over the quarter, and it has been explicit about prioritizing debt reduction. A cheap, deleveraging, brand-rich staple with stabilizing organic sales is a legitimate value thesis, not a lottery ticket. The disagreement is about timing and the safety of the payout, not about whether the company is real.

The promotion problem hiding inside price/mix

There is a subtler force at work behind the thin half-point of volume growth, and it is one packaged-food investors learned to fear in the inflation cycle: promotional spend. When list-price increases exhaust elasticity — when shoppers start trading down to private label or simply buying less — the manufacturer's instinct is to defend shelf velocity with deals: temporary price reductions, multi-buy offers, retailer-funded features. Those promotions show up not as a cut to the headline price but as a drag on net realized price and, ultimately, on margin. A business that needs to spend more to move the same units is a business whose pricing power has already turned. The combination Conagra reported this quarter — barely positive volume, decelerating price/mix, and a sharply compressed operating margin — is precisely the fingerprint of a category leaning harder on promotion to hold its place on the shelf. The headline price went up 1.9%; the question is how much of that the company had to give back in the dark to keep the carts moving, and the margin line suggests the answer is "a lot."

Demand that the GLP-1 era is quietly reshaping

Step back from the quarter and consider the demand backdrop into which all of this lands. Conagra's center-store and frozen portfolio — snacks, processed meats, frozen meals, baking mixes, whipped toppings — sits squarely in the path of two slow-moving forces. The first is the stretched American consumer, trading down to private label across exactly these categories as grocery budgets tighten. The second, harder to quantify but impossible to ignore, is the spread of appetite-suppressing weight-loss drugs, which by their mechanism reduce snacking and portion sizes in the precise aisles where Conagra makes its living. Neither force was created this quarter, and neither is reflected as a discrete line in the financials. But both pressure volume — the very metric that grew only half a point — and both make the bull case's assumption of a clean demand rebound look less like a base case and more like a hope. A staples company can survive flat volume for a long time. It cannot raise price into shrinking appetite forever.

The quality-of-earnings tell

One more forensic note, because it recurs across the staples sector and Conagra exhibits it cleanly. The company directs investors to adjusted metrics — adjusted EPS, adjusted gross margin, adjusted operating margin, adjusted EBITDA. In a strong quarter, those adjusted numbers strip out genuine noise and clarify the underlying business. The tell is what happens in a weak quarter. Here, the adjusted EPS ($0.39, down 23.5%) is the worse number and the GAAP EPS ($0.42, up 40%) is the prettier one. That inversion is unusual and worth sitting with: it means the underlying operating reality, as management itself defines it, is materially weaker than the statutory headline suggests, with the GAAP figure lifted by items below the operating line. An investor who anchored on "EPS up 40%" would have exactly the wrong read on the business. The clean read is the adjusted one, and the adjusted one is down nearly a quarter.

The kicker

None of this makes Conagra a fraud or a doomed enterprise. It is a real company, with real brands, generating real cash, run by managers who are deleveraging honestly and telling investors more or less the truth. The bear case is not that the lights go out. It is narrower and harder to dismiss: that a 2.4% organic-sales headline was asked to carry a 1.9% sales decline, a 23.5% drop in adjusted earnings, a 213-basis-point margin collapse, and a guidance cut on its back — and that an eighty-percent-plus payout ratio on a falling earnings line is a promise the arithmetic may not let management keep. A nine-percent yield is not a reward the market hands out for nothing; it is the price of a risk, quoted in plain daylight for anyone willing to read past the first sentence of the press release.

The market is not pricing Conagra's dividend as a gift — it is pricing it as a question, and the company's own falling earnings are the part of the answer the headline was built to hide.